Immunotherapy plus chemo before and after surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy given before and after surgery for esophageal cancer. It aims to see if this approach can improve treatment outcomes for patients with a certain stage of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have esophageal squamous cell carcinoma that is stage 3 or 4A, and it is located in the middle part of the chest.
- Your overall health is good (ECOG score 0 or 1, meaning you can do daily activities without help).
- Your kidney and liver function are within normal limits, and your blood counts are adequate.
- You have not had prior immunotherapy or other cancer treatments for this disease.
- You do not have an active autoimmune disease, serious infection, or other uncontrolled health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug tislelizumab to standard chemotherapy before surgery or radiation can improve outcomes for people with resectable esophageal squamous cell carcinoma. It is designed for patients whose cancer is in the chest and has not spread to distant organs.
This trial tests a single immunotherapy drug (tislelizumab) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if it can shrink the tumor and improve outcomes.
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.